Linked Life Data

19070812

Source:http://linkedlifedata.com/resource/pubmed/id/19070812

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2008-12-16
pubmed:abstractText
Androgen privation is considered as the referent first line treatment for metastatic prostate cancer. Based on LHRH agonist, different therapeutic schedule included maximum androgenic blockage, intermittent treatment and associations with other drugs like oestrogen leading to possible hormonal manipulations. Since metastasis is confirmed, immediate treatment with continue LHRH agonist is the French Association of Urology (AFU) AFU recommendations treatment for metastatic prostate cancer but intermittent treatment can be considered as an option.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1166-7087
pubmed:author
pubmed:issnType
Print
pubmed:volume
18 Suppl 7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S332-7
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
[Role of hormonotherapy in the treatment of metastatic prostate cancer].
pubmed:affiliation
Service d'Urologie, Hôpital Foch, Faculté de médecine Paris-Ile-de-France-Ouest, UVSQ, France. t.lebret@hopital-foch.org
pubmed:publicationType
Journal Article, English Abstract